Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 25Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Mesothelioma 2Stomach Neoplasms 1Sarcoma 1SCLC, Extensive Stage 1Recurrence 1Ovarian Neoplasms 1Neutropenia 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 12pembrolizumab 7Carboplatin 7Cisplatin 6Docetaxel 5sargramostim 4Taxes 4Cyclophosphamide 4Amifostine 4Trastuzumab 3Polymerase Chain Reaction 3Nivolumab 3Irinotecan 3Gemcitabine 3Etoposide 3talazoparib 2aldesleukin 2Vorinostat 2Vinorelbine 2SS1(dsFv)PE38 2Pemetrexed 2Interleukin-12 Subunit p35 2Interleukin-12 2Immunoenzyme Techniques 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Erlotinib Hydrochloride 2tocilizumab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × PM 01183 × Thoracic × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡